Key Points
- Benjamin Palleiko, CEO, sold 3,354 shares on Feb. 12 at an average price of $15.70, netting $52,657.80 and reducing his ownership by 0.78% to 428,286 shares (≈$6.72M).
- KalVista stock opened at $14.91 (1‑year range $9.23–$19.00) with a market cap of about $753.7M and a negative P/E; analysts are mostly bullish, with a consensus rating of "Moderate Buy" and an average price target of $29.17.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 3,354 shares of the company's stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $15.70, for a total value of $52,657.80. Following the sale, the chief executive officer owned 428,286 shares of the company's stock, valued at approximately $6,724,090.20. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
KalVista Pharmaceuticals Stock Down 1.4%
Shares of KalVista Pharmaceuticals stock opened at $14.91 on Friday. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00. The business has a 50-day moving average of $15.63 and a 200-day moving average of $13.82. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a market capitalization of $753.70 million, a PE ratio of -3.77 and a beta of -0.19.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, January 9th. TD Cowen restated a "buy" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen raised shares of KalVista Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, December 6th. Citigroup reaffirmed a "market outperform" rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Citizens Jmp lowered their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a research note on Tuesday, November 11th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.
Get Our Latest Stock Analysis on KALV
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $24,360,000. Parkman Healthcare Partners LLC lifted its holdings in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company's stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the period. Ameriprise Financial Inc. grew its stake in KalVista Pharmaceuticals by 2,258.6% during the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company's stock worth $10,685,000 after buying an additional 905,053 shares during the last quarter. Freestone Grove Partners LP bought a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $8,580,000. Finally, Schroder Investment Management Group boosted its stake in KalVista Pharmaceuticals by 108.7% in the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company's stock valued at $14,145,000 after acquiring an additional 603,499 shares during the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
